Biotechnology · Vancouver, BC V6C 2T8, Canada
$8.50
+4.94% (+$0.40)2026-07-08
Smart-Money SignalNeutral · 52/100— Insiders are net buyers over 90 days ($2.1M, 18 buys vs 0 sales)
Revenue$3.5M
Net Income-$6.5M
EPS$-0.32
Market Cap$185.1M
Price Performance
Historical data including institutional events
Company Profile
M
Michael McFadden
CEO & Executive Director
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The companyâs commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimerâs disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimerâs disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
- Founded
- 2000
- Employees
- 71
- Headquarters
- Vancouver, BC V6C 2T8, Canada
- Website
- www.alphacognition.com
Peer ComparisonRevenue ($B)
▾Loading company sections...